mevalonic acid has been researched along with Mesothelioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badhai, J; Beijersbergen, R; Hulsman, D; Janes, SM; Kolluri, KK; Landman, N; Lieftink, C; Neikes, HK; Pandey, GK; van Lohuizen, M; Vermeulen, M | 1 |
| Ichinomiya, S; Iwata, H; Sato, H; Siddig, S; Suwa, E; Tuerdi, G; Ueno, K; Yano, T | 1 |
| Hida, T; Horio, Y; Murakami-Tonami, Y; Osada, H; Sekido, Y; Tanaka, K | 1 |
| Aldieri, E; Betta, PG; Bosia, A; Gazzano, E; Ghigo, D; Orecchia, S; Pescarmona, G; Riganti, C; Silvagno, F | 1 |
| Bitterman, P; Greatens, T; Kratzke, RA; Polunovsky, VA; Rubins, JB; Tan, AT | 1 |
5 other study(ies) available for mevalonic acid and Mesothelioma
| Article | Year |
|---|---|
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
Topics: Animals; Cholesterol; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mevalonic Acid; Mice; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2023 |
Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromans; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesothelioma; Metabolic Networks and Pathways; Mevalonic Acid; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Vitamin E | 2013 |
Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Hippo Signaling Pathway; Humans; Hyaluronan Receptors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mevalonic Acid; Mutation; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurofibromin 2; Phosphoproteins; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; Signal Transduction; Simvastatin; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; YAP-Signaling Proteins | 2017 |
Asbestos induces nitric oxide synthesis in mesothelioma cells via Rho signaling inhibition.
Topics: Active Transport, Cell Nucleus; Amides; Animals; Asbestos, Crocidolite; Cattle; Cell Line, Tumor; Enzyme Activation; Enzyme Induction; Enzyme Inhibitors; Humans; I-kappa B Kinase; Isoenzymes; Lovastatin; Mesothelioma; Mevalonic Acid; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase; Proto-Oncogene Proteins c-akt; Pyridines; rho GTP-Binding Proteins; Second Messenger Systems; Terpenes | 2007 |
Lovastatin induces apoptosis in malignant mesothelioma cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line; Cell Membrane; Cell Survival; Cytosol; DNA, Neoplasm; Dose-Response Relationship, Drug; Farnesol; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mesothelioma; Mevalonic Acid; Protein Prenylation; ras Proteins; Tumor Cells, Cultured | 1998 |